Please assess the completion status of the following clinical trial:

Trial Title: Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following inclusion criteria to be enrolled in the study:~* 18 years or older~* Histologically or cytologically confirmed metastatic and/or advanced solid tumor (Phase 1 only)~* Phase 2 requires Non-small cell lung cancer (NSCLC); Small-cell lung cancer; Breast adenocarcinoma (female patients only); Squamous cell cancer of the head and neck (HNSCC); or Gastroesophageal adenocarcinoma~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse~* Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse~* Voluntary written consent~* Wiling to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures~* Measurable disease (Phase 2 only)~Exclusion Criteria:~Patients meeting any of the following exclusion criteria are not to be enrolled in the study:~* Female patients who are pregnant or lactating~* Serious medical or psychiatric illness that could interfere with protocol completion~* Receipt of more than 2 previous cytotoxic chemotherapeutic regimens (4 previous regimens for breast cancer). There is no limit on the number of prior noncytotoxic therapies~* Prior treatment with Aurora A-targeted agents, including MLN8237~* Prior treatment with high-dose chemotherapy~* Prior allogeneic bone marrow or other organ transplant~* Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of MLN8237~* Symptomatic brain metastasis~* Radiotherapy to greater than 25% of bone marrow~* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected~* Myocardial infarction within 6 months of enrollment~* Uncontrolled cardiovascular condition~* Major surgery within 14 days of first dose of MLN8237~* Active infection requiring systemic therapy, or other serious infection~* Inability to swallow oral medication~* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C~* Patients requiring full systemic anticoagulation~* History of uncontrolled sleep apnea syndrome~* Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MLN8237 (Alisertib) (Type: EXPERIMENTAL): MLN8237 administered as an enteric-coated tablet (ECT)

Based on this trial design, predict the completion outcome and termination type (if applicable).